We earn revenue through drug development agreements, software licenses, and consulting, with the first being our primary interest.
Drug Development Milestone Agreements:
Development of new molecules or repurposing/repackaging of existing molecules, identification of meaningful biomarkers/clinical endpoints for said molecules, with major focus on immunotherapies and respiratory health
Software licensing:
Patented tools in the areas of: Protein-protein and protein-ligand interaction analysis and docking, quantum and classical molecular dynamics, clinical trial analysis, and generalized graph analysis for biopharma and other cross-industry use cases through ours and third-party biomolecular modeling platforms.
Consulting:
“What is the complexity of your existing bioinformatics workflow? Can quantum methodologies help with this? How can we actually work towards meaningful automation rather than AI without I? How can we go beyond the blindspots of ML/AI in computational biology and chemistry?” These are questions we regularly work on with healthcare institutions and biopharma companies.
As we hit more proof points with our software tools and hardware integrations, we foresee other quantum computing providers and computational resource companies interested in multi-application quantum technologies being our customers either directly or indirectly as resellers.
We make quantum algorithms and hardware integrations that augment existing drug discovery workflows. We advance quantum technologies in two areas - topological data analysis and quantum chemistry. We also verify these work at scale by working with collaborators on unique drug candidates.